troglitazone has been researched along with n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ban, JO; Han, SB; Hong, JT; Kang, KW; Moon, DC; Oh, JH; Son, SM; Song, HS; Song, MJ; Won, D | 1 |
1 other study(ies) available for troglitazone and n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea
Article | Year |
---|---|
Troglitazone, a PPAR agonist, inhibits human prostate cancer cell growth through inactivation of NFκB via suppression of GSK-3β expression.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Chromans; Dose-Response Relationship, Drug; G1 Phase; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Immunoblotting; Male; Microscopy, Fluorescence; NF-kappa B; PPAR gamma; Prostatic Neoplasms; Resting Phase, Cell Cycle; RNA Interference; Thiazoles; Thiazolidinediones; Troglitazone; Urea | 2011 |